This brand name is authorized in Austria, Brazil, Canada, Estonia, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Turkey, United Kingdom, United States
The drug VITRAKVI contains one active pharmaceutical ingredient (API):
|
1
Larotrectinib
UNII PF9462I9HX - LAROTRECTINIB
|
|
Larotrectinib is an adenosine triphosphate (ATP)-competitive and selective tropomyosin receptor kinase (TRK) inhibitor. The TRK family of proteins, TRKA, TRKB, and TRKC, is encoded by NTRK1, NTRK2 and NTRK3 genes. Larotrectinib was rationally designed to avoid activity with off-target kinases. It is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| VITRAKVI Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
| VITRAKVI Oral solution | European Medicines Agency (EU) | MPI, EU: SmPC | |
| VITRAKVI Capsule / Oral solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01EX12 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 538920030030007, 538920030030107, 538920040030407 |
| Country: CA | Health Products and Food Branch | Identifier(s): 02490315, 02490323, 02490331 |
| Country: EE | Ravimiamet | Identifier(s): 1801145, 1801156, 1801167 |
| Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 167776, 429452, 499084 |
| Country: FR | Base de données publique des médicaments | Identifier(s): 64373909, 65942815, 67022406 |
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 377474, 392356, 392359 |
| Country: HK | Department of Health Drug Office | Identifier(s): 66491, 66492, 66493 |
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 8549, 8737 |
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 4291071M1029, 4291071M2025, 4291071S1028 |
| Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1088495, 1088496, 1088497, 1092623 |
| Country: NL | Z-Index G-Standaard, PRK | Identifier(s): 206156, 206164, 206172 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100426670, 100426718, 100426760 |
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699546156382, 8699546156399, 8699546650040 |
| Country: US | FDA, National Drug Code | Identifier(s): 50419-390, 50419-391, 50419-392, 71777-390, 71777-391, 71777-392 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
